Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 3Phase 2/3 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 13Colorectal Neoplasms 9Neoplasm Metastasis 8Peritoneal Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Appendiceal Neoplasms 6Stomach Neoplasms 5Carcinoma, Hepatocellular 5Anus Neoplasms 5Sarcoma 4Rectal Neoplasms 4Colonic Neoplasms 4Liver Neoplasms 3Carcinoma, Transitional Cell 3Pseudomyxoma Peritonei 2Mesothelioma, Malignant 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Anal Canal Carcinoma 2Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pleural Neoplasms 1Pancoast Syndrome 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × Mitomycin × Clear all
NCT07189793 2025-09-24

OHAI-NMIBC-01

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
106 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03658304 2024-11-05

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

University of Florida

Phase 2 Completed
29 enrolled 11 charts
Genitourinary

Carcinoma, Transitional Cell

NCT03558503 2022-09-16

OPTIMA II

UroGen Pharma Ltd.

Phase 2 Completed
63 enrolled 27 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡